Mingchao Xie

AstraZeneca (United States) — United States

Medicine · Health Sciences

17h-index9.1kcitations61works11.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(29), Cancer Genomics and Diagnostics(27), Epigenetics and DNA Methylation(23), Immune cells in cancer(12), vaccines and immunoinformatics approaches(10)

Publications61 total

Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer
Molecular Cancer·2025· 2 citedOpen Access
299P: First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE
Journal of Thoracic Oncology·2025
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Molecular Cancer·2024· 32 citedOpen Access
1505 Spatial profiling of the SCLC tumor microenvironment defined by high MHC-I expression reveals association with functionally relevant antigen presentation
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Erratum to “Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project”
Annals of Oncology·2023Open Access
Supplementary Figures 10 and 11 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Table S3 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
2023Open Access
Table S4 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
2023Open Access
Supplementary Figures 1 and 2 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Data from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Data from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Supplementary Figure 3-7 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Supplementary Table 1 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Supplementary Figures 10 and 11 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Supplementary Methods from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Table S3 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
2023Open Access
Supplementary Methods from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Supplementary Figures 1 and 2 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Supplementary Figures 8 and 9 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2023Open Access
Figure S1-12 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Kai Ye(14), Theresa A. Proia(14), Maneesh Kumar Singh(14), Richard Woessner(14), Larissa S. Carnevalli(14), Gayathri Bommakanti(14), Łukasz Magiera(14), Srimathi Srinivasan(14), Shaun Grosskurth(14), Michael P. Collins(14), Chris Womack(14), Matthew Griffin(14), Minwei Ye(14), Susan Cantin(14), Deanna L. Russell(14), Adina Hughes(14), Nanhua Deng(14), Deanna A. Mele(14), Stephen E. Fawell(14), Simon T. Barry(14)